62
Participants
Start Date
October 31, 2005
Primary Completion Date
October 31, 2011
Study Completion Date
October 31, 2011
Bevacizumab (Avastin)
10 mg/kg IV every 14 days, repeat cycle every 28 days
Erlotinib
150 mg orally every day continuous dosing, repeat cycle every 28 days
UT MD Anderson Cancer Center, Houston
Collaborators (1)
Genentech, Inc.
INDUSTRY
M.D. Anderson Cancer Center
OTHER